Ipamorelin
$59.99
In stockIpamorelin is an investigational synthetic peptide composed of five amino acids. It is classified as a growth hormone secretagogue, meaning it stimulates the release of growth hormone. It acts through the growth hormone secretagogue, or ghrelin, receptor pathway to encourage the pituitary gland to release the body’s own growth hormone.
| SKU | RC-ST-IPA-10MG |
|---|---|
| Manufacturer | Strandix Peptides |
| Form | Lyophilized Powder |
| Strength | 10 mg |
| Size | 3 mL Vial |
| Reported Result | See matching batch report |
| Stock | In stock |
| Documentation Status | Client-supplied report available |
Product Description
Ipamorelin is an investigational synthetic peptide composed of five amino acids. It is classified as a growth hormone secretagogue, meaning it stimulates the release of growth hormone. It acts through the growth hormone secretagogue, or ghrelin, receptor pathway to encourage the pituitary gland to release the body’s own growth hormone.
Interest in ipamorelin centers on its ability to influence growth hormone signaling and its relatively selective activity in early research.
What research has shown:
Growth hormone release in humans: A controlled study in healthy men found that intravenous ipamorelin produced a temporary increase in growth hormone, with levels peaking approximately 40 minutes after administration and declining afterward.
Selective hormonal activity in animals: Research in rats and pigs demonstrated growth hormone release. In pigs, ipamorelin produced comparatively little stimulation of ACTH and cortisol, distinguishing it from some earlier growth hormone-releasing peptides. This does not establish that it is free of hormonal side effects in people.
Storage and handling: Keep unopened lyophilized material sealed, protected from light and moisture, and stored according to the manufacturer label and current COA. Product-specific reconstituted stability must be supported by manufacturer data.
Third-party testing status.
| Batch / Lot | Reported Result | Tested | Partner | Status | Document |
|---|---|---|---|---|---|
| IPA10/2025-12-18-B | 99.777%; 99.731% | Jan 5, 2026 | Janoshik | Client-supplied report | View COA |
.png)